This site may require a log-in in the near future. We are constantly being swamped by AI agents. If they continue to take down the site, we will be changing to requiring logins to access any item.

🍽️ ranolazine,(prescription)

AI Engines For more Details: Perplexity  Kagi Labs  You 

  1. Chronic Stable Angina: Ranolazine is indicated for the treatment of chronic stable angina, which is chest pain or discomfort that occurs when the heart muscle doesn't get enough oxygen-rich blood. By inhibiting the late sodium current in cardiac cells, ranolazine helps to improve myocardial blood flow and decrease the frequency of angina episodes.

  2. Reduced Frequency of Angina Episodes: One of the primary effects of ranolazine is to reduce the frequency of angina episodes in individuals with chronic stable angina. By optimizing myocardial oxygen utilization, ranolazine helps to prevent or alleviate chest pain and improve exercise tolerance.

  3. Improvement in Exercise Capacity: Ranolazine may improve exercise tolerance in individuals with chronic stable angina by reducing the frequency and severity of angina episodes during physical activity. This can lead to enhanced physical function and quality of life.

  4. Adjunctive Therapy: Ranolazine is often used as adjunctive therapy in combination with other anti-anginal medications, such as beta-blockers, calcium channel blockers, or nitrates, especially in patients who have not achieved adequate symptom relief with standard treatments alone.

  5. No Effect on Heart Rate or Blood Pressure: Unlike some other anti-anginal medications, ranolazine typically does not affect heart rate or blood pressure significantly. This makes it a suitable option for patients with coexisting conditions such as hypertension or bradycardia.

  6. Cardiovascular Safety: Ranolazine has been shown to have a neutral effect on cardiovascular outcomes such as heart attack (myocardial infarction) and cardiovascular death in patients with chronic stable angina. It does not increase the risk of arrhythmias or sudden cardiac death.

  7. Side Effects: Common side effects of ranolazine may include dizziness, headache, constipation, nausea, and vomiting. It may also cause QT interval prolongation, a type of heart rhythm disturbance, particularly at higher doses or in patients with certain risk factors. Therefore, careful monitoring of the QT interval is recommended during ranolazine therapy.

  8. Dosage and Administration: Ranolazine is usually taken orally, with or without food, as directed by a healthcare professional. The dosage may vary depending on the individual patient's medical condition, kidney function, and other factors. It is essential to follow the prescribed dosage and administration instructions carefully.

  9. Contraindications: Ranolazine is contraindicated in patients with preexisting QT prolongation, severe liver impairment, and concurrent use of potent CYP3A inhibitors or inducers. It should not be used in patients with acute coronary syndrome or those at risk of developing QT prolongation.

;

Check for interactions on Supp.AI   |   📚 PubMed Citations

⚗️ Compensation for antibiotic usage

Data Contradictions — Limits of Certainity

Impacted of ranolazine,(prescription) On Probiotics

Rank Probiotic Impact
species Escherichia coli Reduces

Bacteria Impacted by ranolazine,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

🧙?

📓 Direct Citations 👪👶 Indirect Citations Taxonomy Rank Effect
0 1 Escherichia genus Decreases
0 1 Roseburia genus Decreases
0 1 Agathobacter genus Decreases
0 1 Bacteroides genus Decreases
0 1 Collinsella genus Decreases
0 1 Coprococcus genus Decreases
0 1 Mediterraneibacter genus Decreases
0 1 Odoribacter genus Decreases
0 1 Phocaeicola genus Decreases
0 1 Streptococcus genus Decreases
0 1 Clostridium genus Decreases
0 1 Segatella genus Decreases
0 1 Escherichia coli O25:H16 no rank Decreases
0 1 Clostridium perfringens A no rank Decreases
0 1 Clostridium perfringens C no rank Decreases
0 1 Clostridium perfringens CPE no rank Decreases
0 1 Escherichia coli O145:H34 no rank Decreases
0 1 Escherichia coli O16:H48 no rank Decreases
0 1 Clostridium perfringens D no rank Decreases
0 1 Escherichia coli O141:H4 no rank Decreases
0 1 Clostridium perfringens B no rank Decreases
0 1 Escherichia coli O139:H1 no rank Decreases
0 1 Clostridium perfringens E no rank Decreases
0 1 Escherichia coli O80:H26 no rank Decreases
0 1 Escherichia coli O158:H23 no rank Decreases
0 1 Escherichia coli O84:H7 no rank Decreases
0 1 Escherichia coli O2:K1:H4 no rank Decreases
0 1 Escherichia coli O2:K1:H7 no rank Decreases
0 1 Escherichia coli O78:H51 no rank Decreases
0 1 Escherichia coli O18ac:H14 no rank Decreases
0 1 Escherichia coli O85:H1 no rank Decreases
0 1 Escherichia coli O7:H15 no rank Decreases
0 1 Escherichia coli O68:H12 no rank Decreases
0 1 Escherichia coli O55:H7 no rank Decreases
0 1 Escherichia coli O1:K1:H7 no rank Decreases
0 1 Escherichia coli O15:H12 no rank Decreases
0 1 Escherichia coli O170:H18 no rank Decreases
0 1 Escherichia coli O155:H21 no rank Decreases
0 1 Escherichia coli O19:H7 no rank Decreases
0 1 Escherichia coli O2:K1:H5 no rank Decreases
0 1 Escherichia coli O20:H12 no rank Decreases
0 1 Escherichia coli O111 serogroup Decreases
0 1 Escherichia coli O121 serogroup Decreases
0 1 Escherichia coli O155 serogroup Decreases
0 1 Escherichia coli O177 serogroup Decreases
0 1 Escherichia coli O26 serogroup Decreases
0 1 Escherichia coli O3 serogroup Decreases
0 1 Escherichia coli O5 serogroup Decreases
0 1 Escherichia coli O86 serogroup Decreases
0 1 Escherichia coli O91 serogroup Decreases
0 1 Escherichia coli O103 serogroup Decreases
0 1 Escherichia coli O78 serogroup Decreases
0 1 Escherichia coli O43 serogroup Decreases
0 1 Escherichia coli O119 serogroup Decreases
0 1 Escherichia coli O157 serogroup Decreases
0 1 Escherichia coli O145 serogroup Decreases
0 1 Escherichia coli O1:HNT serotype Decreases
0 1 Escherichia coli O10:K5(L):H4 serotype Decreases
0 1 Escherichia coli O103:H11 serotype Decreases
0 1 Escherichia coli O103:H25 serotype Decreases
0 1 Escherichia coli O104:H21 serotype Decreases
0 1 Escherichia coli O111:H11 serotype Decreases
0 1 Escherichia coli O111:H8 serotype Decreases
0 1 Escherichia coli O112ac:H19 serotype Decreases
0 1 Escherichia coli O114:H49 serotype Decreases
0 1 Escherichia coli O118:H16 serotype Decreases
0 1 Escherichia coli O121:H7 serotype Decreases
0 1 Escherichia coli O123:H11 serotype Decreases
0 1 Escherichia coli O127:H27 serotype Decreases
0 1 Escherichia coli O127:H6 serotype Decreases
0 1 Escherichia coli O128:H2 serotype Decreases
0 1 Escherichia coli O128ac:H12 serotype Decreases
0 1 Escherichia coli O145:H25 serotype Decreases
0 1 Escherichia coli O145:NM serotype Decreases
0 1 Escherichia coli O146:H21 serotype Decreases
0 1 Escherichia coli O153:H2 serotype Decreases
0 1 Escherichia coli O156:H25 serotype Decreases
0 1 Escherichia coli O157:H43 serotype Decreases
0 1 Escherichia coli O157:NM serotype Decreases
0 1 Escherichia coli O165:H25 serotype Decreases
0 1 Escherichia coli O174:H2 serotype Decreases
0 1 Escherichia coli O174:H21 serotype Decreases
0 1 Escherichia coli O174:H8 serotype Decreases
0 1 Escherichia coli O176:H45 serotype Decreases
0 1 Escherichia coli O177:NM serotype Decreases
0 1 Escherichia coli O26:H1 serotype Decreases
0 1 Escherichia coli O28ac:NM serotype Decreases
0 1 Escherichia coli O29:H4 serotype Decreases
0 1 Escherichia coli O32:H37 serotype Decreases
0 1 Escherichia coli O6:H16:CFA/II serotype Decreases
0 1 Escherichia coli O69:H11 serotype Decreases
0 1 Escherichia coli O78:H12 serotype Decreases
0 1 Escherichia coli O79:H7 serotype Decreases
0 1 Escherichia coli O81:NM serotype Decreases
0 1 Escherichia coli O86:H34 serotype Decreases
0 1 Escherichia coli O91:H14 serotype Decreases
0 1 Escherichia coli O91:NM serotype Decreases
0 1 Escherichia coli ONT:H33 serotype Decreases
0 1 Escherichia coli O100:H21 serotype Decreases
0 1 Escherichia coli O121:H19 serotype Decreases
0 1 Escherichia coli O157:H7 serotype Decreases
0 1 Escherichia coli O16:H6 serotype Decreases
0 1 Escherichia coli O89m:H9 serotype Decreases
0 1 Escherichia coli O111:H- serotype Decreases
0 1 Escherichia coli O113:H21 serotype Decreases
0 1 Escherichia coli H20 serotype Decreases
0 1 Escherichia coli O150:H6 serotype Decreases
0 1 Escherichia coli O111:NM serotype Decreases
0 1 Escherichia coli O112ab:H8 serotype Decreases
0 1 Escherichia coli O99:H6 serotype Decreases
0 1 Escherichia coli O26:H11 serotype Decreases
0 1 Escherichia coli O145:H28 serotype Decreases
0 1 Escherichia coli O126:H45 serotype Decreases
0 1 Escherichia coli O2:H6 serotype Decreases
0 1 Escherichia coli O7:H4 serotype Decreases
0 1 Escherichia coli O1:H42 serotype Decreases
0 1 Escherichia coli O25:NM serotype Decreases
0 1 Escherichia coli O25:H1 serotype Decreases
0 1 Escherichia coli O7:K1 serotype Decreases
0 1 Escherichia coli O125ac:K+:H10 serotype Decreases
0 1 Escherichia coli O6:K2:H1 serotype Decreases
0 1 Escherichia coli O152:H23 serotype Decreases
0 1 Escherichia coli O15:H18 serotype Decreases
0 1 Escherichia coli O39:NM serotype Decreases
0 1 Escherichia coli O44:H18 serotype Decreases
0 1 Escherichia coli O2:K2:H1 serotype Decreases
0 1 Escherichia coli O8:H8 serotype Decreases
0 1 Escherichia coli O89m:H10 serotype Decreases
0 1 Escherichia coli O10:H32 serotype Decreases
0 1 Escherichia coli O6:H16 serotype Decreases
0 1 Escherichia coli O157:H- serotype Decreases
0 1 Escherichia coli O45:H2 serotype Decreases
0 1 Escherichia coli O103:H2 serotype Decreases
0 1 Escherichia coli O167:H26 serotype Decreases
0 1 Escherichia coli O104:H4 serotype Decreases
0 1 Escherichia coli O83:H1 serotype Decreases
0 1 Escherichia coli O9:H10 serotype Decreases
0 1 Escherichia coli O78:H4 serotype Decreases
0 1 Escherichia coli O139:H28 serotype Decreases
1 0 Bacteroides fragilis species Decreases
1 0 Coprococcus comes species Decreases
1 0 Mediterraneibacter gnavus species Decreases
1 0 Odoribacter splanchnicus species Decreases
1 0 Phocaeicola vulgatus species Decreases
1 0 Segatella copri species Decreases
1 0 Bacteroides thetaiotaomicron species Decreases
1 0 Escherichia coli species Decreases
1 0 Clostridium perfringens species Decreases
1 0 Streptococcus parasanguinis species Decreases
1 0 Collinsella aerofaciens species Decreases
1 0 Roseburia intestinalis species Decreases
1 0 Agathobacter rectalis species Decreases

Impact of ranolazine,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Abdominal Aortic Aneurysm 0.6 0.6
Acne 0.6 0.6
ADHD 1.4 0.3 3.67
Age-Related Macular Degeneration and Glaucoma 0.5 0.5
Allergic Rhinitis (Hay Fever) 2 0.9 1.22
Allergies 2.5 1.4 0.79
Allergy to milk products 1.5 0.9 0.67
Alopecia (Hair Loss) 0.3 0.3
Alzheimer's disease 2.3 3.5 -0.52
Amyotrophic lateral sclerosis (ALS) Motor Neuron 1.8 0.4 3.5
Ankylosing spondylitis 2.5 0.9 1.78
Anorexia Nervosa 0.5 2.5 -4
Antiphospholipid syndrome (APS) 1.3 1.3
Asthma 2.6 1.1 1.36
Atherosclerosis 1.6 2 -0.25
Atrial fibrillation 1.8 1.5 0.2
Autism 5.4 4.7 0.15
Autoimmune Disease 0.9 0.7 0.29
Barrett esophagus cancer 0.3 -0.3
benign prostatic hyperplasia 0.6 0.3 1
Biofilm 1.5 1.5
Bipolar Disorder 1.1 0.8 0.38
Brain Trauma 0.6 0.8 -0.33
Breast Cancer 0.7 0.7
Cancer (General) 0.3 0.3 0
Carcinoma 1.7 0.9 0.89
Celiac Disease 2.5 0.6 3.17
Cerebral Palsy 0.8 0.8 0
Chronic Fatigue Syndrome 1.8 2.7 -0.5
Chronic Kidney Disease 1.8 1.2 0.5
Chronic Lyme 0.8 -0.8
Chronic Obstructive Pulmonary Disease (COPD) 1.2 1.1 0.09
Chronic Urticaria (Hives) 1.5 1.2 0.25
Coagulation / Micro clot triggering bacteria 1.3 0.8 0.63
Cognitive Function 1.4 1.3 0.08
Colorectal Cancer 4.6 2.3 1
Constipation 1.5 0.6 1.5
Coronary artery disease 2.5 2 0.25
COVID-19 3.3 5 -0.52
Crohn's Disease 5 2.3 1.17
Cushing's Syndrome (hypercortisolism) 0.9 -0.9
cystic fibrosis 1 0.8 0.25
d-lactic acidosis (one form of brain fog) 0.4 0.4
deep vein thrombosis 2.4 1.1 1.18
Denture Wearers Oral Shifts 0.3 0.3
Depression 4.6 3.5 0.31
Dermatomyositis 0.3 0.3
Eczema 1.7 1.1 0.55
Endometriosis 1.9 1.5 0.27
Eosinophilic Esophagitis 0.3 -0.3
Epilepsy 2.7 0.3 8
erectile dysfunction 1.7 1.7
Fibromyalgia 0.7 1.7 -1.43
Functional constipation / chronic idiopathic constipation 3.6 2.5 0.44
gallstone disease (gsd) 2.4 0.5 3.8
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 1.2 0.3 3
Generalized anxiety disorder 2.5 1.6 0.56
giant cell arteritis 0.2 -0.2
Glioblastoma 0.3 -0.3
Gout 0.6 0.5 0.2
Graves' disease 0.6 1.7 -1.83
Gulf War Syndrome 0.8 1.2 -0.5
Halitosis 0.6 0.3 1
Hashimoto's thyroiditis 1.4 0.3 3.67
Heart Failure 2.7 0.6 3.5
Hidradenitis Suppurativa 0.6 0.6
High Histamine/low DAO 1.4 1.4
hypercholesterolemia (High Cholesterol) 0.9 0.9
hyperglycemia 1 0.3 2.33
Hyperlipidemia (High Blood Fats) 0.3 0.3 0
hypersomnia 0.3 -0.3
hypertension (High Blood Pressure 1.5 2.9 -0.93
Hypothyroidism 0.3 -0.3
Hypoxia 1.8 0.6 2
IgA nephropathy (IgAN) 0.6 2.5 -3.17
Inflammatory Bowel Disease 4.7 4 0.18
Insomnia 0.9 1.4 -0.56
Intelligence 1.2 0.6 1
Intracranial aneurysms 0.3 0.6 -1
Irritable Bowel Syndrome 4.2 2.5 0.68
ischemic stroke 1 1.7 -0.7
Liver Cirrhosis 3.8 2 0.9
Long COVID 4.4 2.6 0.69
Low bone mineral density 0.8 -0.8
Lung Cancer 0.6 0.6
Lymphoma 0.6 0.6
Mast Cell Issues / mastitis 0.9 0.3 2
ME/CFS with IBS 0.5 0.9 -0.8
ME/CFS without IBS 1.1 0.3 2.67
membranous nephropathy 0.3 0.3
Menopause 0.3 0.5 -0.67
Metabolic Syndrome 4.5 3.1 0.45
Mood Disorders 3.9 3.5 0.11
multiple chemical sensitivity [MCS] 0.3 0.3
Multiple Sclerosis 2.3 3.1 -0.35
Multiple system atrophy (MSA) 0.2 0.2
myasthenia gravis 0.9 0.7 0.29
neuropathic pain 1.4 -1.4
Neuropathy (all types) 0.3 1.8 -5
neuropsychiatric disorders (PANDAS, PANS) 1 1
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 3.5 1.4 1.5
NonCeliac Gluten Sensitivity 0.6 0.3 1
Obesity 5.1 3.4 0.5
obsessive-compulsive disorder 2.8 2.6 0.08
Osteoarthritis 2 0.6 2.33
Osteoporosis 1.6 0.6 1.67
pancreatic cancer 0.6 0.3 1
Parkinson's Disease 3.9 3.8 0.03
Polycystic ovary syndrome 4 1.6 1.5
Postural orthostatic tachycardia syndrome 0.2 0.3 -0.5
Premenstrual dysphoric disorder 0.3 0.3
primary biliary cholangitis 0.3 0.8 -1.67
Primary sclerosing cholangitis 1 1.1 -0.1
Psoriasis 1.6 1.8 -0.13
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 3.6 2.5 0.44
Rosacea 0.7 -0.7
Schizophrenia 1.9 1.3 0.46
scoliosis 0.7 0.7
Sjögren syndrome 1.8 0.6 2
Sleep Apnea 0.3 1.1 -2.67
Slow gastric motility / Gastroparesis 0.7 0.7
Small Intestinal Bacterial Overgrowth (SIBO) 1.5 1.5
Stress / posttraumatic stress disorder 1.4 1.4 0
Systemic Lupus Erythematosus 3.1 0.8 2.88
Tic Disorder 1.2 0.9 0.33
Tourette syndrome 0.3 0.3 0
Type 1 Diabetes 2.9 1.9 0.53
Type 2 Diabetes 5.5 3.9 0.41
Ulcerative colitis 3.2 4 -0.25
Unhealthy Ageing 2.7 1.2 1.25
Vitiligo 1.2 0.8 0.5

Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.

Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served.   Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA   Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.   Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.   Inventions /Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]